- NuCana recently enrolled the required number of patients to conduct a first interim analysis in Acelarin‘s Phase III study in biliary tract cancer in the 1H of 2022.
- Acelarin has both the FDA's Fast Track Designation and Orphan Drug Designation.
- The company publicized supplementary data for NUC-3373 and NUC-7738. These programs also have significant milestones in 2022, including study initiations and data readouts.
- Investors need to be prepared for these catalysts in 2022. I expect several opportunities to manage an NCNA position.
For further details see:
NuCana: Preparing For A Critical 2022